Lantern Pharma's $4 Million Registered Direct Offering: A Boost for AI-Driven Oncology Drug Development in Texas

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence to transform oncology drug development, announced a definitive agreement for a registered direct offering expected to generate approximately $4 million in gross proceeds. The offering involves the purchase and sale of 3,669,725 shares of common stock, or pre-funded warrants in lieu thereof, at $1.09 per share. In a concurrent private placement, the company will issue unregistered warrants to purchase up to 3,669,725 additional shares at an exercise price of $1.09 per share, potentially generating an additional $4 million in gross proceeds if fully exercised for cash. The offering is expected to close on or about Sept. 30, 2026, subject to customary closing conditions, with Rodman & Renshaw LLC acting as exclusive placement agent.

This financing matters because it provides Lantern Pharma with working capital for general corporate purposes, which the company intends to use to advance its proprietary RADR artificial intelligence and machine-learning platform. RADR is designed to identify patients most likely to benefit from Lantern's therapies and to guide biomarker-driven clinical development, integrating large-scale genomic and biological data with advanced machine learning. The company's pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI.

For Texas, the offering highlights the state's growing role in the biotech and AI sectors. InvestorWire, a specialized communications platform focused on wire-grade press release syndication, is based in Austin, Texas, and is part of the Dynamic Brand Portfolio @ IBN. As a Texas-based entity, InvestorWire's involvement underscores the state's ecosystem for connecting innovative companies with investors. The offering could also draw attention to Texas as a hub for AI-driven drug development, potentially attracting more investment and talent to the region.

Investors and industry watchers should note that the unregistered warrants will become exercisable subject to stockholder approval and will expire five years following that approval. The net proceeds will be used for working capital and other general corporate purposes, which could accelerate Lantern's clinical programs and strengthen its financial position. For the broader biotech industry, this move exemplifies how AI platforms like RADR are reshaping the cost, pace, and precision of oncology drug development, potentially leading to faster and more targeted therapies.

The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN. InvestorWire, a specialized communications platform with a focus on advanced wire-grade press release syndication, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. IBN delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries, as well as article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions.